

**Anti Complement factor D (human)
Mouse Monoclonal Antibody**

Subclass: IgG1/k

 PRODUCT NO. **GAU 008-01**

 PRESENTATION Preparation: Protein-A/G purified
 Content: 200 µL, 1 mg/mL
 Solvent: 0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15mM sodium azide
 Storage: In the dark at 4-8°C

ANTIGEN Complement factor D is a serine protease of the alternative pathway of complement activation. The protein is a single chain polypeptide with a molecular mass of 25 kDa. Factor D cleaves factor B bound to C3b, generating the alternative pathway C3 convertase C3bBb and releasing the Ba fragment.

IMMUNOGEN Human factor D (1)

SPECIFICITY GAU 008-01 is specific for complement factor D in human serum and plasma

EPI TOPE SPECIFICITY Epitope specificity differs from that of GAU 010-04

REACTIVITY GAU 008-01 is used as detection antibody in sandwich ELISA with a GAU 010-04 capture

CULTURE MEDIUM RPMI 1640 with 10% fetal calf serum

FUSION PARTNER X63-Ag8.653.

IMMUNIZATION BALB/c mice immunized i.p.

APPLICATION

| Method | Usability | Dilution guideline | References |
|----------------------|----------------|--------------------|------------|
| ELISA | Yes | 1:1000 | 1 |
| Immunoblotting | Yes | | |
| Immunohistochemistry | Not determined | | |

REFERENCES

1. Oppermann M, Baumgarten H, Brandt E, Gottsleben W, Kurts C, Gotze O (1990) Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosorbent assays. *J Immunol Methods* 133:181-190.
2. Oppermann M, Kurts C, Zierz R, Quentin E, Weber MH, Gotze O (1991) Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure. *Kidney Int.* 40:939-947.
3. Oppermann M, Höpken U, Götze O (1992) Assessment of complement activation in vivo. *Imm. pharm* 24:119-134.

CONDITIONS

All products are supplied on the understanding that they are for in vitro use only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.